AstraZeneca’s EMERALD-3 Trial Shows Promising Results in Liver Cancer

AstraZeneca has reported positive high-level results from its Phase III EMERALD-3 trial evaluating a combination therapy for unresectable hepatocellular carcinoma.

The study assessed Imfinzi and Imjudo—used together as the STRIDE regimen—alongside lenvatinib and transarterial chemoembolisation. Results showed a statistically significant improvement in progression-free survival compared to TACE alone. Early analysis also indicated a positive trend in overall survival.

The global trial involved 760 patients across 171 centres in 22 countries, testing combinations of immunotherapy with and without lenvatinib.

The findings suggest that introducing the STRIDE regimen earlier in treatment could improve outcomes in liver cancer. The safety profile remained consistent with known data, with no new concerns identified.

Further analysis of overall survival and secondary endpoints is ongoing.

06-04-2026